Greenstreet Yvonne — SEC insider filings
SEC reporting owner CIK 1446125. 39 insider filings on record with FilingPulse; latest filed 2026-11-17.
Transaction summary — filings shown
Covers all 39 filings on record, filed 2021-01-13 to 2026-11-17. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 151 legs across 22 filings — 255,331 shares, $73,273,242 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 89.
- Largest priced transaction: sale of 53,064 shares @ $199.00 ($10,559,736) in ALNYLAM PHARMACEUTICALS, INC., filed 2021-08-09.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | Chief Executive Officer, Director | 37 | — | 151 legs · 255,331 sh · $73,273,242 | 85 |
| Pacira BioSciences, Inc. (PCRX) | Director | 2 | — | — | 4 |
Insider filings — Greenstreet Yvonne
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-11-17 | 4 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | Gift (G): 11,000 @ $0 | EDGAR |
| 2026-09-22 | 4 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | Grant/award (A): 107 @ $0 | EDGAR |
| 2026-03-06 | 4 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | Sale (S): 135 @ $319.03 · Sale (S): 129 @ $320.01 · Sale (S): 274 @ $320.81 · Sale (S): 368 @ $321.82 · Sale (S): 444 @ $323.01 · Sale (S): 973 @ $323.84 · +2 more | EDGAR |
| 2026-03-04 | 4 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | Grant/award (A): 13,844 @ $0 · Sale (S): 200 @ $323.62 · Sale (S): 382 @ $324.65 · Sale (S): 1,098 @ $325.63 · Sale (S): 1,669 @ $326.81 · Sale (S): 1,399 @ $327.67 · +7 more | EDGAR |
| 2026-03-02 | 4 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | Option exercise (M): 5,921 @ $0 · Option exercise (M): 5,921 (derivative) @ $0 | EDGAR |
| 2026-02-17 | 4 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | Grant/award (A): 14,209 @ $0 · Sale (S): 6,958 @ $310.08 | EDGAR |
| 2026-01-14 | 4 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | Grant/award (A): 19,003 @ $0 · Sale (S): 247 @ $353.95 · Sale (S): 269 @ $355.16 · Sale (S): 263 @ $356.09 · Sale (S): 607 @ $357.17 · Sale (S): 778 @ $358.18 · +16 more | EDGAR |
| 2025-12-01 | 4 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | Option exercise (M): 839 @ $119.13 · Option exercise (M): 2,352 @ $85 · Option exercise (M): 847 @ $118.05 · Option exercise (M): 659 @ $151.59 · Tax withholding (F): 1,121 @ $445.12 · Option exercise (M): 2,352 (derivative) @ $0 · +3 more | EDGAR |
| 2025-11-14 | 4 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | Option exercise (M): 650 @ $42.22 · Option exercise (M): 15,000 @ $119.13 · Sale (S): 711 @ $448.07 · Sale (S): 2,132 @ $449.15 · Sale (S): 453 @ $450.17 · Sale (S): 1,255 @ $451.16 · +20 more | EDGAR |
| 2025-10-03 | 4 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | Grant/award (A): 3,860 @ $0 · Grant/award (A): 14,252 @ $0 · Sale (S): 350 @ $446.53 · Sale (S): 171 @ $447.92 · Sale (S): 548 @ $448.77 · Sale (S): 758 @ $449.79 · +8 more | EDGAR |
| 2025-08-19 | 4 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | Grant/award (A): 14,252 @ $0 · Sale (S): 194 @ $447.98 · Sale (S): 450 @ $449.92 · Sale (S): 195 @ $450.92 · Sale (S): 514 @ $451.99 · Sale (S): 1,646 @ $452.96 · +3 more | EDGAR |
| 2025-06-03 | 4 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | Option exercise (M): 12,081 @ $119.13 · Option exercise (M): 19,559 @ $118.05 · Sale (S): 25,469 @ $304 · Sale (S): 6,171 @ $306 · Option exercise (M): 12,080 @ $119.13 · Option exercise (M): 7,217 @ $118.05 · +5 more | EDGAR |
| 2025-05-19 | 4 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | Gift (G): 8,376 @ $0 | EDGAR |
| 2025-05-06 | 4 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | Gift (G): 41,311 @ $0 | EDGAR |
| 2025-03-05 | 4 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | Grant/award (A): 17,965 @ $0 · Sale (S): 1,068 @ $242.37 · Sale (S): 1,173 @ $243.36 · Sale (S): 791 @ $244.41 · Sale (S): 580 @ $245.26 · Sale (S): 238 @ $246.18 · +3 more | EDGAR |
| 2025-03-03 | 4 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | Option exercise (M): 5,921 @ $0 · Sale (S): 158 @ $236.51 · Sale (S): 123 @ $238.33 · Sale (S): 127 @ $239.18 · Sale (S): 284 @ $240.32 · Sale (S): 461 @ $241.51 · +4 more | EDGAR |
| 2025-02-18 | 4 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | Grant/award (A): 3,859 @ $0 · Sale (S): 271 @ $252.50 · Sale (S): 300 @ $253.37 · Sale (S): 201 @ $254.35 · Sale (S): 85 @ $255.56 · Sale (S): 98 @ $256.29 · +7 more | EDGAR |
| 2024-11-27 | 4 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | Grant/award (A): 10,658 @ $0 · Sale (S): 93 @ $247.77 · Sale (S): 762 @ $249.60 · Sale (S): 1,131 @ $250.68 · Sale (S): 2,933 @ $251.42 · Sale (S): 300 @ $252.27 | EDGAR |
| 2024-08-22 | 4 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | Option exercise (M): 15,000 @ $85 · Sale (S): 15,000 @ $280 · Option exercise (M): 15,000 (derivative) @ $0 | EDGAR |
| 2024-08-02 | 4 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | Option exercise (M): 15,148 @ $85 · Sale (S): 15,148 @ $270 · Option exercise (M): 15,148 (derivative) @ $0 | EDGAR |
| 2024-07-12 | 4 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | Sale (S): 7,093 @ $261 | EDGAR |
| 2024-06-26 | 4 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | Grant/award (A): 16,953 @ $0 · Sale (S): 308 @ $221.71 · Sale (S): 66 @ $224.17 · Sale (S): 93 @ $225.55 · Sale (S): 177 @ $226.82 · Sale (S): 666 @ $228.30 · +7 more | EDGAR |
| 2024-03-05 | 4 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | Grant/award (A): 23,754 @ $0 · Grant/award (A): 46,394 (derivative) @ $0 | EDGAR |
| 2024-02-29 | 4 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | Option exercise (M): 5,921 @ $0 · Sale (S): 1,259 @ $154.54 · Sale (S): 993 @ $155.45 · Sale (S): 588 @ $156.38 · Sale (S): 84 @ $157.30 · Sale (S): 8 @ $158.09 · +1 more | EDGAR |
| 2024-02-20 | 4 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | Grant/award (A): 16,953 @ $0 · Sale (S): 2,576 @ $147.50 · Sale (S): 3,614 @ $148.24 · Sale (S): 840 @ $149.03 | EDGAR |
| 2023-08-07 | 4 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | Grant/award (A): 5,082 @ $0 · Grant/award (A): 3,859 @ $0 · Sale (S): 771 @ $184.70 · Sale (S): 1,869 @ $185.54 · Sale (S): 1,107 @ $186.39 · Sale (S): 101 @ $187.37 · +2 more | EDGAR |
| 2023-04-28 | 4 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | Grant/award (A): 16,952 @ $0 · Sale (S): 628 @ $193.18 · Sale (S): 2,898 @ $193.93 · Sale (S): 3,225 @ $194.94 · Sale (S): 331 @ $195.65 · Sale (S): 533 @ $197.08 | EDGAR |
| 2023-03-01 | 4 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | Grant/award (A): 17,763 (derivative) @ $0 · Grant/award (A): 36,775 (derivative) @ $0 | EDGAR |
| 2022-08-05 | 4 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | Grant/award (A): 5,083 @ $0 · Grant/award (A): 4,153 @ $0 · Grant/award (A): 3,859 @ $0 · Tax withholding (F): 5,433 @ $189.76 · Tax withholding (F): 195 @ $209.83 · Tax withholding (F): 194 @ $209.85 · +1 more | EDGAR |
| 2022-06-08 | 4 | Pacira BioSciences, Inc. (PCRX) | Grant/award (A): 1,160 @ $0 · Grant/award (A): 8,225 (derivative) @ $0 | EDGAR |
| 2022-02-25 | 4 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | Grant/award (A): 31,747 (derivative) @ $0 | EDGAR |
| 2022-01-04 | 4 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | Grant/award (A): 55,949 (derivative) @ $0 | EDGAR |
| 2021-12-23 | 4 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | Grant/award (A): 5,417 @ $0 · Tax withholding (F): 2,415 @ $189.13 · Tax withholding (F): 1 @ $190.96 · Tax withholding (F): 122 @ $186.55 | EDGAR |
| 2021-08-09 | 4 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | Option exercise (M): 28,064 @ $77.10 · Option exercise (M): 25,000 @ $77.10 · Sale (S): 53,064 @ $199 · Option exercise (M): 25,000 (derivative) @ $0 · Option exercise (M): 28,064 (derivative) @ $0 | EDGAR |
| 2021-06-11 | 4 | Pacira BioSciences, Inc. (PCRX) | Grant/award (A): 1,066 @ $0 · Grant/award (A): 7,626 (derivative) @ $0 | EDGAR |
| 2021-04-21 | 4 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | Grant/award (A): 5,083 @ $0 · Tax withholding (F): 2,266 @ $131.75 · Tax withholding (F): 85 @ $134.49 | EDGAR |
| 2021-02-26 | 4 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | Grant/award (A): 28,800 (derivative) @ $0 | EDGAR |
| 2021-02-16 | 4 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | Grant/award (A): 5,416 @ $0 · Tax withholding (F): 1,841 @ $156 · Tax withholding (F): 104 @ $155.84 · Grant/award (A): 8,334 (derivative) @ $0 | EDGAR |
| 2021-01-13 | 4 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | Option exercise (M): 3,125 @ $42.22 · Sale (S): 3,125 @ $161 · Option exercise (M): 3,125 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2020-10-05 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1446125 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs